



Pharming Group N.V.

H.C. Wainwright 27th Annual
Global Investment Conference

September 2025


NASDAQ: **PHAR** | EURONEXT Amsterdam: **PHARM**

This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", "anticipate", "believe", "could", "estimate", "expect", "goals", "intend", "may", "milestones", "objectives", "outlook", "plan", "probably", "project", "risks", "schedule", "seek", "should", "target", "will" and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this presentation are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this presentation and are based on information available to Pharming as of the date of this presentation. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Combination of commercial and pipeline assets poised to deliver strong value creation



Commercial

Pipeline



***Develop a leading global rare disease company
with a diverse portfolio and presence in large markets,
leveraging proven and efficient clinical development,
supply chain, and commercial infrastructure***

Strong second quarter 2025 performance



- Total revenues up 26%
- Meaningful operating profit and cash generated from operations
- Continued double-digit RUCONEST® revenue growth
- Double-digit Joenja® revenue growth with accelerating patient uptake
- Raised 2025 revenue guidance to US\$335-350 million

* Adjusted operating profit for 2Q 2025 excludes US\$2.1 million of non-recurring Abliva acquisition-related expenses.




RUCONEST® for HAE

RUCONEST® (rhC1INH)


Targets the root cause of HAE across all pathways


Only recombinant treatment that targets the root cause of HAE by replacing C1-INH

Only recombinant treatment that acts at multiple points in the cascades leading to HAE attacks



- ◆ Type 1, Type 2, and Normal C1-INH HAE patients rely on RUCONEST
- ◆ 97% attacks treated with just 1 dose¹
- ◆ 93% acute attacks stopped for at least 3 days²
- ◆ RUCONEST® mostly used by patients experiencing more severe/frequent attacks








Joenja[®] (leniolisib)
APDS & PID indications

APDS is a rare primary immunodeficiency (PID)


Genetic defect leads to PI3K δ hyperactivity

Hyperactive PI3K δ results in dysregulated B and T cell development¹⁻³




Note: Illustration does not include all steps in the signaling pathway.

Immune imbalance leads to diverse signs and symptoms^{1,4-6}



Severe, recurrent, persistent infections

- Sinopulmonary
- Herpesvirus (especially EBV and CMV)




Lymphoproliferation

- Lymphadenopathy
- Splenomegaly/hepatomegaly
- Nodular lymphoid hyperplasia



Enteropathy



Autoimmunity

- Cytopenias
- Autoimmune disorders
- Autoinflammatory disorders



Bronchiectasis



Lymphoma


FOXO, forkhead box O; mTOR, mammalian target of rapamycin; PI3K δ , phosphoinositide 3-kinase delta; PKB, protein kinase B.

1. Lucas CL, et al. *Nat Immunol.* 2014;15(1):88-97. 2. Fruman DA, et al. *Cell.* 2017;170(4):605-635. 3. Okkenhaug K, Vanhaesebroeck B. *Nat Rev Immunol.* 2003;3(4):317-330. 4. Coulter TI, et al. *J Allergy Clin Immunol.* 2017;139(2):597-606. 5. Elkaim E, et al. *J Allergy Clin Immunol.* 2016;138(1):210-218. 6. Jamee M, et al. *Clin Rev Allergy Immunol.* 2020;59(3):323-333.

24-year-old male with APDS whose progress was followed in the Joenja[®] open-label extension study for 6 years

	Before study enrollment	Since starting Joenja treatment
Infections and treatment burden	• Experienced fatigue from IRT infusions, anxiety, and difficulty coping with treatment burden • Hospitalized yearly for infections • Frequently prescribed antibiotics	• Stopped IRT infusions and fatigue got better • No hospitalizations • He had 7 infections, none of which returned • Only doctor he visits regularly is his immunologist
Clinical manifestations	• Low blood platelet counts • Damaged lung airways • Gastrointestinal issues and migraines	• Blood platelet count increased • Damaged lung airways did not get worse

Joenia® acceleration in patient growth in 12y+ APDS



Reclassification of VUS* patients 2H25

- >1400 patients in the US with VUS results
- June 2025 publication in *Cell* supports functional classification of >100 variants
- 20% patients could ultimately be diagnosed with APDS

Pediatric label expansion 1H26

- FDA filing for 4-11 years pediatrics in July 2025
- Approval expected in 1H26
- > 50 US pediatric patients, many already on drug

Geographic Expansion *ongoing*


- Launched and reimbursed in the UK
- Japan NDA for ages 4+ filed June 2025
- Japan, EU and Canada approvals expected in 2026
- 150 APDS patients in access programs and clinical studies

*Variant of Uncertain Significance (VUS): Inconclusive results due to limited data on variant pathogenicity

Joenja® (leniolisib) lifecycle to realize \$1Bn+ sales potential



U.S. patient numbers ONLY shown to illustrate prevalence
Geo expansion – UK, EU4, Japan, Australia, Canada + access programs



*Initial estimate of APDS prevalence is ~1.5 patients / million. 257 patients, approximately 25% of whom are pediatric, currently identified in the U.S. out of ~500 total. 971 patients, approximately 33% of whom are pediatric, currently identified globally. (Data as of June 30, 2025)

Leniolisib development in PIDs with immune dysregulation: Significant expansion of addressable patient population

Patient Population


- PID patients with clinical manifestations similar to APDS
- Significant unmet clinical need, no approved therapies
- Prevalence 5-26x APDS

Rationale

- Critical role of PI3K δ in lymphocyte regulation, driving lymphoproliferation and autoimmunity
- Positive experience in compassionate use patients

Two Phase II studies underway

- Genetically defined PIDs with immune dysregulation¹
- Common variable immunodeficiency (CVID) with immune dysregulation²
- On track for 2026 read-outs



1. PIDs include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency and PTEN deficiency, amongst others. Prevalence 7.5 patients / million

2. Prevalence 39 patients/million



Pharming®

KL1333 for mtDNA
Mitochondrial Disease

KL1333 for mtDNA-driven primary mitochondrial disease

Aiming for the first disease-modifying treatment

KL1333 targets underlying pathology

- Normalizes NAD⁺/NADH ratio and mitochondrial function, with evidence from in vitro data, animal models, and in patients treated with KL1333


Significant patient population

- >30,000 diagnosed patients with mtDNA disorders¹
- Majority of patients treated in centers of excellence²

Registrational clinical study underway

- Clinically-relevant endpoints, supported by FDA
- Positive interim analysis in pivotal study
- Expect readout in 2027 and FDA approval end of 2028

Dysfunctional mitochondria



Pivotal FALCON Study

WAVE 1 – Fully enrolled

- ◆ 40 patients recruited across six countries (U.S., UK, France, Spain, Belgium, Denmark)
- ◆ Interim analysis at 24 weeks

WAVE 2 – Enrolling

- ◆ 180 total patients treated for 48 weeks
- ◆ All Wave 1 sites + three new sites active (n=20)
- ◆ Planning 40+ total sites, with significant expansion in the US
- ◆ Readout anticipated 2027

Interim Futility Analysis

Positive outcome achieved, with both primary endpoints passing futility

- ◆ Promising differences favoring the active arm vs. placebo for both primary efficacy endpoints
- ◆ Data monitoring committee (DMC) concluded:
 - Safety and tolerability profile acceptable
 - No changes to study design
 - 180 total patients confirmed in the study



Outlook

◆ Revenue and operating expenses:

	FY 2025 Guidance	Notes
Total Revenues	US\$335 - 350 million	13 - 18% growth
Operating Expenses	US\$304 - 308 million	Assumes constant currency, Includes \$10.2 million non-recurring Abliva-related transaction and integration expenses

◆ RUCONEST® well positioned to provide continued strong cash flows

◆ Available cash and future cash flows expected to cover current pipeline and pre-launch costs

Strong start to 2025

Strong RUCONEST® growth and acceleration of Joenja® patient uptake.

2Q25 revenues +26%
1H25 revenues +33%

Achieved operating profit

Updated 2025 guidance

Raised revenue guidance to US\$335 - 350M

High value pipeline

Joenja® (leniolisib) for PIDs/CVID with immune dysregulation

KL1333 for mtDNA mitochondrial disease

Significant catalysts

Joenja® for APDS: VUSs, pediatric label, geo expansion (2025-26)

Higher APDS prevalence

Leniolisib PIDs/CVID PhII readouts (2026)

KL1333 pivotal study readout (2027)



www.pharming.com


NASDAQ: **PHAR** | EURONEXT Amsterdam: **PHARM**



Pharming Group N.V.

Appendix

Diverse rare disease portfolio and pipeline




APDS: Heterogeneous, evolving symptomology can often lead to missed diagnoses

Timeline of the most common pathologies* seen in APDS¹⁻⁴

Median age at diagnosis:
12 years (7-year median diagnosis delay)



APDS has often been diagnosed as another PI or condition, causing delays in diagnosis¹



Improved identification of symptoms, increased genetic testing, and earlier diagnosis are needed

*Pathologies can occur at any time.

[†]In Elkaim APDS2 cohort, median age of bronchiectasis is 13; in Maccari ESID cohort, median age is 11.2.

[‡]No median ages are available for these manifestations.

ALPS, autoimmune lymphoproliferative syndrome; CID, combined immunodeficiency; CVID, common variable immune deficiency; ESID, European Society for Immunodeficiencies; HIGM, hyper immunoglobulin M syndrome; IgG, immunoglobulin G; PI3Kδ, phosphoinositide 3-kinase delta; XLA, X-linked agammaglobulinemia.


1. Jamee M, et al. *Clin Rev Allergy Immunol*. 2020;59(3):323-333. 2. Maccari ME, et al. *Front Immunol*. 2018;9:543. 3. Elkaim E, et al. *J Allergy Clin Immunol*. 2016;138(1):210-218.e9. 4. Coulter TI, et al. *J Allergy Clin Immunol*. 2017;139(2):597-606.

Cell

Article

Scalable generation and functional classification of genetic variants in inborn errors of immunity to accelerate clinical diagnosis and treatment

Graphical abstract



Authors

Zachary H. Walsh, Chris J. Frangieh, Neeharika Kothapalli, ..., Dusan Bogunovic, Joshua D. Milner, Benjamin Izar

Correspondence

jdm2249@cumc.columbia.edu (J.D.M.), bi2175@cumc.columbia.edu (B.I.)

In brief

In lieu of traditional genetic variant testing approaches, an approach using scalable variant classification in primary human T cells with a clinically relevant readout can inform rapid diagnosis and treatment of inborn errors of immunity.

VUS patients: Inconclusive genetic test due to insufficient data to determine if variant is disease causing

Study uncovered >100 new variants leading to PI3K δ hyperactivity (GOF variants)

Leniolisib restored / improved PI3K δ signaling defects and immune abnormalities caused by GOF variants



Data suggests that VUS patients with these GOF variants should be reclassified as APDS

Genetic test labs will utilize data to independently re-assess VUSs and reclassify patients to APDS*

Expand studies to functionally evaluate the remainder of all possible variants in APDS genes

Frequency of new GOF variants in population databases is significantly higher than current understanding of APDS


Study concludes that APDS may be up to 100x more prevalent than previously estimated with broader clinical features

Population-based studies planned to refine the genetic prevalence and clinical manifestations of APDS using biobanks

* Over 1,400 known U.S. patients with a variant of uncertain significance, or VUS, in the PIK3CD and PIK3R1 genes implicated in APDS

Joenia: Targeting the root cause of APDS to help restore immune balance

- ❖ Treatment with Joenia in a randomized, controlled-trial led to:
 - Significant improvements in immune dysregulation (e.g, lymph node and splenomegaly reductions)
 - Significant improvements in immunophenotype
- ❖ Favorable Safety Profile
 - No serious AEs were related to Joenia treatment
 - No patients withdrew from the clinical trials due to an adverse drug reaction
 - The most common adverse reactions (incidence >10%) in the phase 3 trial were headache, sinusitis, and atopic dermatitis
- ❖ Long-term open-label study
 - Median duration of Joenia exposure was ~2 years
 - Reduction in infections (see right)



Pivotal Trial - Part 1: Dose- finding^{1,2}



Nonrandomized, open-label,
dose-escalating



6 patients with APDS



12 weeks



10 mg, 30 mg, 70 mg bid
(4 weeks each dose)



70 mg bid selected for Part 2

Pivotal Trial - Part 2: Efficacy & Safety Evaluation³



Randomized, triple-blinded,
placebo-controlled



31 patients with APDS
(21 Joenja[®], 10 placebo)



12 weeks



70 mg bid



Co-primary efficacy end points

- Change from baseline in log¹⁰-transformed SPD of index lesions
 - Also assessed as % change
- Change from baseline in percentage of naïve B cells out of total B cells

Secondary and exploratory end points
Safety

Open-label extension study^{4,5}



Nonrandomized, open-label,
long-term study



• 35 patients with APDS from
Parts 1 and 2

• 2 patients with APDS previously
treated with investigational
PI3Kδ inhibitors



Ongoing



70 mg bid



Long-term safety, tolerability,
efficacy, and pharmacokinetics

bid, twice a day; PI3Kδ, phosphoinositide 3-kinase delta; SPD, sum of product diameters


1. Rao VK, et al. *Blood*. 2017;130(21):2307-2316. 2. NCT02435173. ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT02435173>. Updated May 6, 2015. Accessed March 13, 2023. 3. Rao VK, et al. *Blood*. 2023;141(9):971-983.

4. NCT02859727. ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT02859727>. Updated October 31, 2022. Accessed March 3, 2023. 5. Data on file. Pharming Healthcare Inc; 2022.


Joenia® addresses the underlying cause of APDS to help restore immune balance – Phase 3 co-primary endpoints

At 12 weeks Joenia® decreased lymphadenopathy and increased naïve B cells

Immune Dysregulation



Immune Deficiency



Data were analyzed using an ANCOVA model with treatment as a fixed effect and baseline as a covariate. Use of glucocorticoids and IRT at baseline were both included as categorical (Yes/No) covariates. Baseline is defined as the arithmetic mean of the baseline and D1 values when both are available, and if either baseline or the D1 value is missing, the existing value is used. P-value is 2-sided. Least square means are graphed. Error bars are standard error of the mean.

*The analysis excluded 2 patients from each treatment group due to protocol deviations and 1 Joenia patient having complete resolution of the index lesion identified at baseline.

†Out of 27 patients in the PD analysis set, 13 patients met the analysis requirements, including having a percentage of <48% of naïve B cells at baseline, to form the B-PD analysis set.

Joenia [package insert]. Leiden, The Netherlands: Pharming Technologies B.V.; 2023.

Please see Important Safety Information and full Prescribing Information available at joenia.com


Secondary endpoint: Significant reductions in spleen size by 2D and 3D analysis compared to placebo

- The adjusted mean difference in bidimensional spleen size between Joenia[®] (n=19) and placebo (n=9) was -13.5 cm^2 (95% CI: $-24.1, -2.91$), $P=0.0148$
- The adjusted mean difference in 3D spleen volume between Joenia[®] (n=19) and placebo (n=9) was -186 cm^3 (95% CI: $-297, -76.2$), $P=0.0020$

at week 12
27%
reduction in 3D spleen volume*

Secondary measure: spleen volume scan results of actual patient illustrate average improvement documented for patients taking Joenia[®]

Prior to treatment:
491 mL



At week 12:
314 mL



Actual patient images of a 17-year-old male. As individual results vary, images may not be representative of all patients.

Rao VK, et al. Blood. 2023;141(9):971-983.

*In the PD analysis set, the mean (SD) percentage change from baseline to week 12 in 3D spleen volume (mm^3) was -26.68% (12.137) with Joenia[®] (n=19) and -1.37% (24.238) with placebo (n=9). The ANCOVA model was used with treatment as a fixed effect and $\log_{10}$ -transformed baseline as a covariate for index and non-index lesions. The use of both glucocorticoids and IV Ig at baseline was included as categorical (yes/no) covariates.

This analysis excluded 2 patients in each treatment group. In the Joenia[®] group, 1 patient with a complete index lesion response was excluded, and 3 patients were excluded for no non-index lesion at baseline. PD, pharmacodynamics.

Phase 3 Trial^{1,2}

Adverse reactions reported by ≥2 patients treated with Joenja and more frequently than placebo

	Joenja (n=21) n (%)	Placebo (n=10) n (%)
Headache	5 (24)	2 (20)
Sinusitis	4 (19)	0
Dermatitis atopic*	3 (14)	0
Tachycardia [†]	2 (10)	0
Diarrhea	2 (10)	0
Fatigue	2 (10)	1 (10)
Pyrexia	2 (10)	0
Back pain	2 (10)	0
Neck pain	2 (10)	0
Alopecia	2 (10)	0

- Study drug-related AEs occurred in 8 patients; the incidence was lower in the Joenja arm (23.8%) than in the placebo arm (30.0%)
- No AEs led to discontinuation of study treatment

A patient with multiple occurrences of an AE is counted only once in the AE category. Only AEs occurring at or after first drug intake are included.

*Includes dermatitis atopic and eczema. [†]Includes tachycardia and sinus tachycardia.

AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SAE, serious adverse event.

1. Rao VK, et al. Blood. 2023;141(9):971-983. 2. Joenja [package insert]. Leiden, The Netherlands: Pharming Technologies B.V.; 2023. 3. Data on file. Pharming Healthcare Inc; 2022.

Please see Important Safety Information and full Prescribing Information available at joenja.com

Open-label Extension Study³

Data cutoff for interim analysis: December 13, 2021



- 32/37 patients reported ≥1 AE
- 78.4% of AEs were grade 1, 48.6% grade 2, 27.0% grade 3, 0% grade 4
- No SAEs related to Joenja

Most common AEs	n
Upper respiratory tract infection	8
Headache	6
Pyrexia	6
Otitis externa	5
Weight increase	5
COVID-19, positive/negative	5/14

One patient with significant baseline cardiovascular comorbidities suffered cardiac arrest resulting in death at extension Day 879; determined by investigator not to be related to study drug

- Across all trials²**
- 38 patients had a **median exposure of ~2 years**
 - 4 patients had **>5 years of exposure**

Open-label extension interim analysis of days spent with infections and IRT reduction



Although safety was the primary objective of the open-label study, this post hoc analysis from the open-label study was not powered to provide any statistical significance of efficacy and therefore no conclusions should be drawn.

*Infections that developed during the study were reported as adverse events. Investigators were requested to inquire about signs and symptoms of infections at each visit, with a particular focus on bacterial enterocolitis. Patients were not provided an infection diary to document infections occurring between visits. One patient was excluded from the analysis due to an incorrect year that was recorded for an infection.

[†]Baseline infections are each group's year 1 annual rate of infections. N values changed because patients were in the OLE for different lengths of time. [‡]Data on concomitant medication usage was reported at each patient visit.

[§]One patient had a subsequent one-time dose. ^{||}One patient achieved IRT freedom for 3 months but subsequently restarted IRT. IRT, immunoglobulin replacement therapy; m, number of infection days; N, number of patients in follow-up category.

Rao VK, et al. Poster presented at: 64th Annual American Society of Hematology Annual Meeting; December 10-13, 2022; New Orleans, LA.

Please see Important Safety Information and full Prescribing Information available at joenja.com

Pediatric


Phase III trial for children 4-11 years old with APDS

Positive topline data announced December 2024

- ◆ 21 patients enrolled in U.S., Europe, and Japan
- ◆ Both co-primary endpoints show improvement consistent with the RCT in adolescents and adults
- ◆ Benefits seen across the four tested dose levels
- ◆ No deaths/discontinuations due to AEs. No new safety findings
- ◆ Data to be presented at CIS conference in May
- ◆ Regulatory filings beginning with the U.S. in second half 2025

Joenja[®] development status

Expanding the addressable patient population



* Anticipate regulatory action in 2026 for Canada

Genetically defined PIDs with immune dysregulation linked to PI3Kδ

- Single arm, open-label, dose range-finding (N=12)
- Patients with PIDs linked to PI3Kδ signaling, e.g. ALPS-FAS¹, CTLA4 haploinsufficiency², NFKB1 haploinsufficiency³, PTEN deficiency⁴
- Primary: Safety & Tolerability
- Secondary/Exploratory: PK/PD, efficacy measures
- 10/30/70 mg BID: 4/4/12 wks treatment, respectively
- Lead investigator: Gulbu Uzel, M.D., Senior Research Physician, Co-Investigator: V. Koneti Rao, M.D., FRCPA, Senior Research Physician, Primary Immune Deficiency Clinic (ALPS Clinic) (NIH)



Common variable immunodeficiency (CVID) with immune dysregulation

- Single arm, open-label, dose range-finding (N=20)
- Patients with a CVID diagnosis, evidence of lymphoproliferation, and at least one additional clinical manifestation of immune dysregulation
- Primary: Safety & Tolerability
- Secondary/Exploratory: PK/PD, efficacy measures
- 10/30/70 mg BID: 4/4/16 wks treatment, respectively
- Multi-center study (US, UK, EU)
- Lead investigator: Jocelyn Farmer, MD, PhD, Director of the Clinical Immunodeficiency Program (Beth Israel Lahey Health)



1. Bride K & Teachey D. F1000Res. 2017;6:1928. ; Rao VK & Oliveria JB. Blood 2011; 118(22):5741-51.
2. Kuehn HS, et al. Science 2014; 345:1623-27. ; Schwab C, et al. J Allergy Clin Immunol. 2018;142(6):1932-1946.
3. Lorenzini T, et al. J Allergy Clin Immunol. 2020;146:901-11.
4. Eissing M, et al. Transl Oncol. 2019;12(2):361-367. ; Tsujita, et al. J Allergy Clin Immunol. 2016;138(6):1872-80.

Primary mitochondrial disease (PMD)

Heavy patient burden with no approved therapies

Presentation and Diagnosis

- ◆ Patients present to their primary care doctor and then often get referred to a neurologist for musculoskeletal issues
- ◆ Either the neurologist or a referral to a metabolic geneticist will result in a diagnosis
- ◆ Many patients are diagnosed at academic centers specializing in mitochondrial disease
- ◆ A combination of routine lab tests and genetic testing available from major testing labs help to diagnose patients

Impact

- ◆ Patients heavily burdened in their daily lives including symptoms like severe fatigue, myopathy, and metabolic dysfunction
- ◆ Impact on QoL including loss of job, loss of independence, depression/anxiety
- ◆ Primary mitochondrial diseases lead to a three-to-four-decade reduction in life-expectancy

Treatment

- ◆ No approved treatment options
- ◆ Patients are limited to using vitamins, supplements, and physical therapy


“On the worst days I will be crying in frustration because going to the kitchen seems equivalent to climbing a mountain and just trying to process what others are saying to me involves all the energy and concentration that I have.”

United Mitochondrial Disease Foundation, Voice of the Patient Conference, 2019

Primary Mitochondrial Disease (PMD)

- ❖ Mitochondria, often described as the “powerhouses” of cells, are crucial for energy production
- ❖ PMD is a group of disorders caused by mutations in mitochondrial (mtDNA) or nuclear DNA, resulting in impaired electron transport chain (ETC) function
- ❖ Disrupted ETC function alters the NAD^+/NADH ratio, reducing ATP production
- ❖ Patients experience severe fatigue and muscle weakness – often the most troublesome symptoms*

Dysfunctional Mitochondria



Decreased energy production




Decreased mitochondria biogenesis

*Voice of the Patient Report, United Mitochondrial Disease Foundation, 2019.


NAD: Nicotinamide adenine dinucleotide; NADH: Nicotinamide adenine dinucleotide + hydrogen; ETC: Electron transport chain.

KL1333 normalizes conversion of NADH to NAD⁺ via NQO1

Normalizes the NAD⁺/NADH Ratio






Restored Energy Metabolism



The placebo-controlled Phase 1b study demonstrated that KL1333 reduced patients' fatigue and myopathy after only 10 days, 50 mg/day

- ◆ KL1333 demonstrated efficacy in the phase 1b placebo-controlled portion with patients diagnosed with mtDNA mitochondrial disease
 - Fatigue reduction (NeuroQoL fatigue change)
 - Muscle function improvement (30 seconds sit-to-stand)
- ◆ KL1333 showed efficacy signals after 10 days using 50 mg/day
- ◆ Mitochondrial patients have increased lactate levels and increasing the concentration of KL1333 resulted in an improved lactate/pyruvate ratio, reflecting target engagement
- ◆ No serious adverse events reported



KL1333 pivotal FALCON study

Design informed by regulatory and patient advocacy input

Regulatory Feedback

- Both FDA and EMA accepted study as registrational
- FDA said achieving one of the two endpoints would be sufficient for filing
- Conducted regular and detailed discussions with the FDA to facilitate alignment

Study Design


- Methodology**
 - Randomized, double-blind, parallel-group, placebo-controlled pivotal study
- Patients Included**
 - Adult PMD patients with mtDNA mutations* with fatigue and myopathy
- Primary Endpoints**
 - Fatigue using the PROMIS Fatigue Mitochondrial Disease Short Form
 - Muscle weakness using the 30 second Sit-to-Stand test

Week 24
Interim futility analysis
(Wave 1 only)

Week 48
Primary efficacy analysis


Week 53
Safety follow-up

Study Schematic



*Most prevalent mtDNA disorders include m.3243A>G associated MELAS-MIDD spectrum disorders, single large scale mtDNA deletion associated KSS-CPEO spectrum disorders, other multisystemic mtDNA-related disease (including MERRF)

Significant revenue opportunity for KL1333



>30,000 diagnosed mtDNA mitochondrial disease patients addressable in the US, EU4 and UK

*mtDNA mutations including m.8344A>G MELAS-MIDD, MERRF, KSS-CEPO, large scale mtDNA deletions







¹Gorman, G.S. et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol 2015 May;77(5):753-9.

²Gorman, G.S. et al. Mitochondrial Diseases. Nat. Rev. Vol 2, 1-22 (2016).

Majority of mitochondrial disease patients diagnosed and treated in US Centers of Excellence or academic institutions









Financial highlights: 2Q 2025 vs 2Q 2024



* Adjusted operating profit for 2Q 2025 excludes US\$2.1 million of non-recurring Abliva acquisition-related expenses (US\$1.9 million in G&A, \$0.2 million in R&D).







Financial highlights: 1H 2025 vs 1H 2024



* Adjusted operating profit for 1H 2025 excludes US\$9.9 million of non-recurring Abliva acquisition-related expenses (US\$7.6 million in G&A, \$2.3 million in R&D).

** Decrease in cash primarily driven by purchases of Abliva shares totaling US\$66.1 million and non-recurring Abliva acquisition-related expenses totaling US\$9.9 million.

Financial highlights: FY 2024 vs FY 2023



* Operating profit (loss) for 2023 excludes milestone payments for Joenja® (US\$10.5 million) and gain on sale of Priority Review Voucher to Novartis (US\$21.3 million).

** US\$30.4 million of the US\$45.6 million decrease in overall cash and marketable securities is due to convertible bond refinancing.